Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depressive disorder: a systematic review and network meta-analysis.

IF 21.1 1区 医学 Q1 PSYCHIATRY
Paul C F van Haaren, Jakob M van Gaalen, Edoardo G Ostinelli, Kiyomi Shinohara, Aran Tajika, Rosario Aronica, Nobuatsu Aoki, Eduarda Batista, Suzanne A Ligthart, Christiaan H Vinkers, Orestis Efthimiou, Andrea Cipriani, Toshi A Furukawa, Henricus G Ruhé
{"title":"Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depressive disorder: a systematic review and network meta-analysis.","authors":"Paul C F van Haaren, Jakob M van Gaalen, Edoardo G Ostinelli, Kiyomi Shinohara, Aran Tajika, Rosario Aronica, Nobuatsu Aoki, Eduarda Batista, Suzanne A Ligthart, Christiaan H Vinkers, Orestis Efthimiou, Andrea Cipriani, Toshi A Furukawa, Henricus G Ruhé","doi":"10.1016/S2215-0366(26)00326-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Major depressive disorder carries high risks of relapse and chronicity, necessitating treatments that achieve and maintain response (sustained response). This study aimed to compare antidepressants on their ability to achieve sustained response, and on acceptability, by synthesising data from randomised controlled trials.</p><p><strong>Methods: </strong>For this systematic review and network meta-analysis, we searched the Cochrane Register, AMED, CINAHL, Embase, LILACS, MEDLINE, MEDLINE In-Progress, PsycINFO, the UK National Research Register, and regulatory agency websites from inception to March 27, 2026. We included double-blind randomised controlled trials that compared any of 21 antidepressants head-to-head or with placebo for long-term treatment (>12 weeks) of adult unipolar major depressive disorder. We included enrichment, non-enrichment, continuation, and continuation-extension designs, and extracted study-level data. We could not derive the sex or gender distribution of participants other than female and did not extract data on race or ethnicity. Primary outcomes were efficacy (sustained response rate) and acceptability (all-cause discontinuation). We synthesised data in random-effects pairwise and network meta-analyses to estimate pooled odds ratios (ORs), using fluoxetine as a reference in the ranked forest plots. The primary analysis included head-to-head continuation and continuation-extension design studies. Enrichment design studies were incorporated in the analysis using a chain-of-evidence approach. Risk-of-bias assessment was done using the Cochrane Risk of Bias 2 tool. No people with lived experience were involved in the design, conduct, or interpretation of this study.</p><p><strong>Findings: </strong>From 54 231 records, 115 studies (30 428 participants; mean age 45·3 years [SD 8·5], 20 066 [66%] female) were included. In head-to-head continuation and continuation-extension design studies (35 studies; n=9888), sustained response differed across antidepressants. Escitalopram (OR 1·62, 95% CI 1·21-2·18), duloxetine (OR 1·57, 1·08-2·26), and agomelatine (OR 1·40, 1·06-1·85) showed higher sustained response rates than fluoxetine. Bupropion and reboxetine showed lower sustained response rates against four other antidepressants in the league table of pairwise comparisons. Escitalopram (OR 0·60, 0·43-0·83) and duloxetine (OR 0·64, 0·44-0·95) demonstrated lower all-cause discontinuation compared with fluoxetine, while reboxetine and milnacipran showed higher all-cause discontinuation against six and four other antidepressants, respectively, in the league table of pairwise comparisons. Sensitivity analyses incorporating enrichment-design studies corroborated these results. However, the certainty of evidence of the network meta-analysis results and the risk of bias in the included studies (19 [54%] of 35 had high risk of bias) might limit the reliability of the current findings.</p><p><strong>Interpretation: </strong>Antidepressants can differ in their efficacy for achieving sustained response and in their acceptability. These findings can inform the shared decision making for patients, prescribers, and carers in real-world practice. However, more head-to-head comparative studies are needed to provide reliable information about long-term effects of all licensed antidepressants.</p><p><strong>Funding: </strong>None.</p>","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":""},"PeriodicalIF":21.1000,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2215-0366(26)00326-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Major depressive disorder carries high risks of relapse and chronicity, necessitating treatments that achieve and maintain response (sustained response). This study aimed to compare antidepressants on their ability to achieve sustained response, and on acceptability, by synthesising data from randomised controlled trials.

Methods: For this systematic review and network meta-analysis, we searched the Cochrane Register, AMED, CINAHL, Embase, LILACS, MEDLINE, MEDLINE In-Progress, PsycINFO, the UK National Research Register, and regulatory agency websites from inception to March 27, 2026. We included double-blind randomised controlled trials that compared any of 21 antidepressants head-to-head or with placebo for long-term treatment (>12 weeks) of adult unipolar major depressive disorder. We included enrichment, non-enrichment, continuation, and continuation-extension designs, and extracted study-level data. We could not derive the sex or gender distribution of participants other than female and did not extract data on race or ethnicity. Primary outcomes were efficacy (sustained response rate) and acceptability (all-cause discontinuation). We synthesised data in random-effects pairwise and network meta-analyses to estimate pooled odds ratios (ORs), using fluoxetine as a reference in the ranked forest plots. The primary analysis included head-to-head continuation and continuation-extension design studies. Enrichment design studies were incorporated in the analysis using a chain-of-evidence approach. Risk-of-bias assessment was done using the Cochrane Risk of Bias 2 tool. No people with lived experience were involved in the design, conduct, or interpretation of this study.

Findings: From 54 231 records, 115 studies (30 428 participants; mean age 45·3 years [SD 8·5], 20 066 [66%] female) were included. In head-to-head continuation and continuation-extension design studies (35 studies; n=9888), sustained response differed across antidepressants. Escitalopram (OR 1·62, 95% CI 1·21-2·18), duloxetine (OR 1·57, 1·08-2·26), and agomelatine (OR 1·40, 1·06-1·85) showed higher sustained response rates than fluoxetine. Bupropion and reboxetine showed lower sustained response rates against four other antidepressants in the league table of pairwise comparisons. Escitalopram (OR 0·60, 0·43-0·83) and duloxetine (OR 0·64, 0·44-0·95) demonstrated lower all-cause discontinuation compared with fluoxetine, while reboxetine and milnacipran showed higher all-cause discontinuation against six and four other antidepressants, respectively, in the league table of pairwise comparisons. Sensitivity analyses incorporating enrichment-design studies corroborated these results. However, the certainty of evidence of the network meta-analysis results and the risk of bias in the included studies (19 [54%] of 35 had high risk of bias) might limit the reliability of the current findings.

Interpretation: Antidepressants can differ in their efficacy for achieving sustained response and in their acceptability. These findings can inform the shared decision making for patients, prescribers, and carers in real-world practice. However, more head-to-head comparative studies are needed to provide reliable information about long-term effects of all licensed antidepressants.

Funding: None.

抗抑郁药在重度抑郁症长期治疗中的比较疗效和可接受性:一项系统综述和网络荟萃分析。
背景:重度抑郁症具有复发和慢性的高风险,需要实现和维持反应(持续反应)的治疗。本研究旨在通过综合随机对照试验的数据,比较抗抑郁药物获得持续反应的能力和可接受性。方法:在本系统综述和网络荟萃分析中,我们检索了Cochrane Register、AMED、CINAHL、Embase、LILACS、MEDLINE、MEDLINE In-Progress、PsycINFO、英国国家研究注册和监管机构网站,时间从成立到2026年3月27日。我们纳入了双盲随机对照试验,比较了21种抗抑郁药物中的任何一种或安慰剂对成人单极重性抑郁症的长期治疗(bb0 - 12周)。我们纳入了浓缩、非浓缩、延续和延续-扩展设计,并提取了研究水平的数据。我们无法得出除女性之外的参与者的性别或性别分布,也没有提取有关种族或民族的数据。主要结局是疗效(持续缓解率)和可接受性(全因停药)。我们综合了随机效应两两分析和网络荟萃分析的数据,以氟西汀作为分级森林样地的参考,估计合并优势比(or)。主要分析包括头对头延续和延续-延伸设计研究。利用证据链方法将浓缩设计研究纳入分析。使用Cochrane Risk of Bias 2工具进行偏倚风险评估。本研究的设计、实施或解释均不涉及有生活经验的人。结果:从54 231份记录中,纳入115项研究(30 428名参与者,平均年龄45.3岁[SD 8.5],女性20 066名[66%])。在头对头延续和延续-延伸设计研究(35项研究;n=9888)中,抗抑郁药的持续反应不同。艾司西酞普兰(OR 1.62, 95% CI 1.21 - 2.18)、度洛西汀(OR 1.57, 1.08 - 2.26)和阿戈美拉汀(OR 1.40, 1.06 - 1.85)的持续缓解率高于氟西汀。安非他酮和瑞波西汀在两两比较的排名表中显示出比其他四种抗抑郁药更低的持续反应率。艾司西酞普兰(OR为0.60,0.43 - 0.83)和度洛西汀(OR为0.64,0.44 - 0.95)的全因停药率低于氟西汀,而瑞波西汀和米那西普兰的全因停药率分别高于其他6种和4种抗抑郁药。敏感性分析结合富集设计研究证实了这些结果。然而,网络荟萃分析结果证据的确定性和纳入研究的偏倚风险(35项研究中有19项[54%]存在高偏倚风险)可能会限制当前研究结果的可靠性。解释:抗抑郁药在实现持续反应的功效和可接受性方面可能有所不同。这些发现可以为患者、处方医生和护理人员在现实世界的共同决策提供信息。然而,需要更多的正面对比研究来提供有关所有许可的抗抑郁药的长期效果的可靠信息。资金:没有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lancet Psychiatry
Lancet Psychiatry PSYCHIATRY-
CiteScore
58.30
自引率
0.90%
发文量
0
期刊介绍: The Lancet Psychiatry is a globally renowned and trusted resource for groundbreaking research in the field of psychiatry. We specialize in publishing original studies that contribute to transforming and shedding light on important aspects of psychiatric practice. Our comprehensive coverage extends to diverse topics including psychopharmacology, psychotherapy, and psychosocial approaches that address psychiatric disorders throughout the lifespan. We aim to channel innovative treatments and examine the biological research that forms the foundation of such advancements. Our journal also explores novel service delivery methods and promotes fresh perspectives on mental illness, emphasizing the significant contributions of social psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书